Indeed, EZH2 inhibition has been shown to restore AR expression and sensitivity to antiandrogen therapy in preclinical models of advanced PCa, suggesting epigenetic reprogramming as a promising approach to bypass antiandrogen therapy resistance [164]. Here, EZH2 is linked to posterior cortical atrophy.